United Therapeutics

UTHRApproved

Silver Spring, United StatesFounded 1996unither.com

United Therapeutics Corporation is a biotechnology company dedicated to developing life-saving medicines for patients with rare diseases, particularly pulmonary arterial hypertension. Founded in 1996 by Dr. Martine Rothblatt, the company has successfully commercialized multiple breakthrough therapies and continues to advance innovative treatment approaches including gene therapy and xenotransplantation. With a strong financial position and diversified product portfolio, United Therapeutics is well-positioned to maintain its leadership in rare disease therapeutics.

Market Cap

$23.0B

Founded

1996

Employees

1,000-1,500

Focus

Generic DrugsSmall MoleculesCell & Gene Therapy

UTHR · Stock Price

USD 524.28+349.44 (+199.86%)

Historical price data

AI Company Overview

Technology Platform

United Therapeutics develops innovative drug delivery systems and formulations focused on prostacyclin pathway therapeutics, while also advancing gene therapy and xenotransplantation technologies for rare diseases and organ transplantation.

Pipeline Snapshot

133

133 drugs in pipeline, 32 in Phase 3

Drug	Indication	Stage
Remodulin (treprostinil sodium)	Pulmonary Arterial Hypertension	Approved
treprostinil sodium	Pulmonary Hypertension	Approved
Parenteral Treprostinil + Oral Treprostinil	Pulmonary Arterial Hypertension	Approved
treprostinil sodium	Pulmonary Arterial Hypertension	Approved
Slow Dose Titration Group of Subcutaneous Treprostinil + Rapid Dose Titration Gr...	Pulmonary Arterial Hypertension	Approved

Funding History

Total raised: $560M

Debt$500MUndisclosedAug 15, 2020

IPO$60MUndisclosedMay 27, 1999

FDA Approved Drugs

ACETAMINOPHEN AND IBUPROFENANDAFeb 28, 2023

TYVASO DPINDAMay 23, 2022

NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDEANDAMay 10, 2019

Opportunities

United Therapeutics has significant growth opportunities through pipeline advancement in gene therapy and xenotransplantation, geographic expansion of existing products, and potential acquisition of complementary rare disease assets.

The company's strong cash position enables strategic investments in breakthrough technologies.

Risk Factors

Key risks include increasing competition in core PAH markets, potential generic competition as patents expire, regulatory challenges for novel technologies like xenotransplantation, and the inherent risks of clinical development in rare diseases with small patient populations.

Competitive Landscape

United Therapeutics competes with Janssen, Bayer, GSK, and Acceleron in the PAH market but maintains leadership through its comprehensive prostacyclin franchise and innovative delivery systems. The company differentiates itself through patient-focused drug delivery innovations and pioneering work in xenotransplantation and gene therapy for rare diseases.

Publications

Pipeline

133

FDA Approvals